Biocytogen, a biomedical contract research organization (CRO) specialized in gene-targeted animal models and services, announced on Thursday that it has raised RMB543 million (US$77.11 million) in a series D round of financing.
Chinese Biomedical CRO Biocytogen Raises $77M In Series D Round comes originally from China Money Network. All Rights Reserved.